Condition (MeSH)
Pityriasis Rubra Pilaris
ClinicalTrials.gov lists 6 trials for Pityriasis Rubra Pilaris or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
6 of the 6 trials are tagged with Pityriasis Rubra Pilaris itself; the rest are tagged with a narrower condition beneath it.
When did Pityriasis Rubra Pilaris trials start? (5)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 4
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 1 |
| 2019 | 1 |
| 2018 | 2 |
| 2008 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 6 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Pityriasis Rubra Pilaris trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 4 | 2 |
How many Pityriasis Rubra Pilaris trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Completed | 4 |
| Terminated | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which serious adverse events do Pityriasis Rubra Pilaris trials report? (1)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cholecystitis leading to myocardial infarction and death | 1 | 1 |
Which publications cover Pityriasis Rubra Pilaris? (3)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling: A Nonrandomized Trial. | JAMA dermatology | 2024 | Yes |
| Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis. | The British journal of dermatology | 2022 | Yes |
| Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial. | JAMA dermatology | 2020 | Yes |
Prevalence (4)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Pityriasis rubra pilaris | Cases families | Worldwide | Not stated | Exact | |
| Pityriasis rubra pilaris | Point prevalence | 1-9 / 1 000 000 | Worldwide | Not stated | Exact |
| Pityriasis rubra pilaris | Cases families | Worldwide | Not stated | Exact | |
| Pityriasis rubra pilaris | Point prevalence | 1-9 / 1 000 000 | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Pityriasis rubra pilaris | 2897 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Pityriasis rubra pilaris | 2897 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.